Atomoxetine-Associated Eyebrow Alopecia in a Girl With Attention-Deficit/Hyperactivity Disorder

An 8-year-old girl with Attention-Deficit/Hyperactivity Disorder (ADHD) experienced bilateral eyebrow loss after treatment with atomoxetine, a nonpsychostimulant agent commonly used for ADHD. This is the first reported case of eyebrow alopecia associated with atomoxetine treatment. The girl had no history of alopecia, dermatological disease, or specific drug reactions, and was not exposed to other medications, heavy metals, toxins, or stressors while taking atomoxetine. After discontinuing the medication, her eyebrows returned to their normal state after 36 days without any other medications or dietary supplements. Atomoxetine was reintroduced after 50 days due to ADHD symptoms, but no signs of eyebrow alopecia were observed. The exact mechanisms of eyebrow alopecia and drug tolerance are still unknown, but adverse effects were noted to be transient, occurring mainly early in atomoxetine treatment and then declining. Clinicians should be aware that eyebrow alopecia is a possible but very rare adverse effect of atomoxetine treatment.